Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of Glioblastomas.

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03115138

Acronym

Bi-GLAM

Enrollment

Registered

2017-04-14

Start date

2016-03-09

Completion date

2017-11-06

Last updated

2020-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma, Molecular Disease

Keywords

Biopsy

Brief summary

Glioblastomas (GBM) are rare tumors of poor prognosis and their treatment is based on surgery followed by radiochemotherapy. Clinical and imaging evaluation is not always straightforward: the more or less complete surgery, the pseudo-progression after radiochemotherapy, the radionecrosis, the diagnosis of the relapse and the follow-up under anti-angiogenic can pose problems Clinicians and radiologists. Accessibility to a plasma tumor molecular marker would greatly facilitate the follow-up of these patients. It is now established for many cancers that circulating tumor DNA (cTNA) has the same molecular abnormalities as those identified in the primary tumor cells. Numerous studies have shown the prognostic value and diagnosis of the exploration of cDNA.

Interventions

OTHERCorrelation between molecular anomalies of the primary tumor and circulating tumor DNA

The presence of a specific abnormality initially identified on the primary tumor and which can be quantified in the cDNA during the management will allow a better follow-up of the patient.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with grade IV glial tumor (glioblastoma according to WHO criteria) for which an indication of surgical excision with radiochemotherapy was chosen at a specialized multidisciplinary meeting of neuro-oncology at the CHU Amiens-Picardy. * Patients should: * be able to be followed at the CHU of Amiens throughout their treatment, * be at least 18 years of age, * be informed (or trusted) of the conditions and objectives of the study, * having given their free and informed consent in writing, * have a life expectancy of more than 6 months, * be affiliated to a social security scheme.

Exclusion criteria

* Patients with recurrent tumors. * Patients supported for another histology. * Medical, psychological or social conditions that do not allow for proper understanding of the procedures inherent in the study. * Patients under tutelage, curatorship.

Design outcomes

Primary

Measure	Time frame
Presence of a correlation between the molecular abnormalities of the primary tumor and the circulating tumor DNA	1 year

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026